Hayleigh Collins | Director and Head of Corporate Communications |
Sean Nolan | Chief Executive Officer |
Sukumar Nagendran | President and Head of Research and Development |
Kamran Alam | Chief Financial Officer |
Whitney Ijem | Canaccord Genuity |
Jack Allen | Robert W. Baird & Co. |
Silvan Tuerkcan | JMP Securities |
Yun Zhong | BTIG |
David Hoang | SMBC Nikko Securities |
Joon Lee | Truist Securities |
Greetings, and welcome to the Taysha Gene Therapies Fourth Quarter and Full-Year 2022 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Hayleigh Collins, Director and Head of Corporate Communications.